Treatment for glioblastoma (GBM)
This site is intended for US healthcare professionals only.

Recurrent GBM quality of life

Quality of life: Cognitive and emotional functioning

Quality of life for patients treated with Optune® for glioblastoma (GBM): cognitive and emotional functioning

*Therapy options were the physician's best choice for chemotherapy, including bevacizumab, which were defined given historical assessment of effective recurrent GBM therapies. The best available therapy was prescribed according to local practice and depending on prior treatment exposure.
  • Data collected by EORTC QLQ-C30 questionnaire

  • Improvements in cognitive and emotional functioning observed with Optune

Quality of life: Common cancer treatment-related adverse symptoms

Quality of life for patients treated with Optune®:  common cancer treatment-related adverse symptoms

*Therapy options were the physician's best choice for chemotherapy, including bevacizumab, which were defined given historical assessment of effective recurrent GBM therapies. The best available therapy was prescribed according to local practice and depending on prior treatment exposure.
  • Data collected by EORTC QLQ-C30 questionnaire

  • Changes in patient-reported symptoms

EORTC, European Organisation for Research and Treatment of Cancer; GBM, glioblastoma; TMZ, temozolomide

Reference: 1. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.Eur J Cancer. 2012;48(14):2192-2-202.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).